Replimune (REPL) Change in Acquisitions & Divestments (2018 - 2026)
Replimune (REPL) reported Change in Acquisitions & Divestments of $90.5 million for Q1 2026, up 39.03% on a YoY basis from $65.1 million in Q1 2025, and down 11.11% sequentially from $101.8 million in Q4 2025.
Replimune (REPL) Change in Acquisitions & Divestments (2018 - 2026) Analysis & Trends
Replimune (REPL) has 9 years of Change in Acquisitions & Divestments data on file, last reported at $90.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 39.03% year-over-year to $90.5 million; the trailing twelve-month figure through Mar 2026 stood at $393.0 million (up 1.68% YoY), and the FY2026 full-year result was $393.0 million, up 1.68% from the prior year.
- Change in Acquisitions & Divestments retreated to $90.5 million in Q1 2026, from $101.8 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $177.1 million in Q2 2023 to a low of $60.0 million in Q1 2022.
- A 5-year average of $110.3 million and a median of $105.4 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
- Across the five-year window, Change in Acquisitions & Divestments soared 164.39% in 2023 and sank 51.2% in 2025, its largest moves.
- Tracing REPL's Change in Acquisitions & Divestments over 5 years: stood at $115.7 million in 2022, then surged by 34.46% to $155.5 million in 2023, then tumbled by 40.53% to $92.5 million in 2024, then grew by 10.02% to $101.8 million in 2025, then retreated by 11.11% to $90.5 million in 2026.
- Business Quant data shows REPL's Change in Acquisitions & Divestments at $90.5 million in Q1 2026, $101.8 million in Q4 2025, and $95.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.46 Mn |
| Mar 31, 2026 | 90.46 Mn |
| Dec 31, 2025 | 101.77 Mn |
| Dec 31, 2025 | 101.77 Mn |
| Sep 30, 2025 | 95.36 Mn |
| Sep 30, 2025 | 95.36 Mn |
| Jun 30, 2025 | 105.37 Mn |
| Jun 30, 2025 | 105.37 Mn |
| Mar 31, 2025 | 65.07 Mn |
| Mar 31, 2025 | 65.07 Mn |
| Dec 31, 2024 | 92.50 Mn |
| Dec 31, 2024 | 92.50 Mn |
| Sep 30, 2024 | 92.00 Mn |
| Sep 30, 2024 | 92.00 Mn |
| Jun 30, 2024 | 136.91 Mn |
| Jun 30, 2024 | 136.91 Mn |
| Mar 31, 2024 | 133.34 Mn |
| Mar 31, 2024 | 133.34 Mn |
| Dec 31, 2023 | 155.54 Mn |
| Dec 31, 2023 | 155.54 Mn |